BML Capital Management’s LAVA Therapeutics LVTX Stock Holding History

BML Capital Management’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,970,610	Closed	-$3.07M	–	21
2025 Q3	$3.07M	Hold	1,970,610	–	–	2.81%	8
2025 Q2	$2.6M	Buy	1,970,610 +10,000	+0.5%	+$12.7K	1.97%	12
2025 Q1	$2.49M	Buy	+1,960,610	New	+$2.18M	2.02%	12

BML Capital Management's LVTX Position: Q4 2025 in Review

BML Capital Management sold out of LAVA Therapeutics (LVTX) in Q4 2025, closing a stake of 1,970,610 shares — an estimated $3.07M sold.

BML Capital Management first reported a position in LVTX in Q1 2025 and held it in 3 quarters. The position peaked at $3.07M in Q3 2025. 0 funds tracked by Wall St. Rank hold LVTX as of Q4 2025.

BML Capital Management reported no remaining LAVA Therapeutics position as of Q4 2025 after selling out during the quarter.
BML Capital Management sold 1,970,610 LAVA Therapeutics shares in Q4 2025, an estimated $3.07M.
BML Capital Management first reported a position in LAVA Therapeutics in Q1 2025 and held it in 3 quarters.
BML Capital Management's LAVA Therapeutics position peaked at $3.07M in Q3 2025.
0 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2025.

Based on BML Capital Management's 13F filing for Q4 2025, filed 3 Feb 2026.